What We're Reading: Page 151
Industry reads hand-picked by our editors
Sep 09, 2021
-
The Wall Street Journal
White House Unveils Plan to Cut Prescription-Drug Prices
-
STAT
FDA rejection of Humanigen drug points to industry challenge in Covid fight
-
Evaluate Vantage
Centessa takes a step towards a new hemophilia mechanism
Sep 08, 2021
-
Bloomberg
Feared Wall Street Fund Elliott Is Targeting GSK. What Does It Want?
-
FierceBiotech
SPAC Attack: The 10 biggest in biotech
-
Financial Times
Top Pfizer scientist defends Covid vaccine booster push and jab’s potency
-
Smithsonian Magazine
Frog Foam May Help Deliver Drugs to Human Skin
Sep 07, 2021
-
Bloomberg
One Vaccine Makes More Antibodies Than Another. Does it Matter?
-
MIT Technology Review
Meet Altos Labs, Silicon Valley’s latest wild bet on living forever
-
FiercePharma
Crippled by opioid-crisis litigation, Mallinckrodt settlement brings company closer to reorganization
-
STAT
CEPI warns of major hurdle to developing new Covid-19 vaccines
Sep 03, 2021
Sep 02, 2021
-
Associated Press
Judge conditionally approves Purdue Pharma opioid settlement
-
The Boston Globe
MassBio taps another state lawmaker as its leader
-
The Washington Post
House committees step up investigation into FDA approval of controversial Alzheimer’s drug
-
Bloomberg Law
FDA Regains Rulemaking Authority in Reversal of Trump-Era Move
Sep 01, 2021
Aug 31, 2021
-
POLITICO
CDC vaccine panel: Let regulators lead on Covid-19 booster shots
-
MedPage Today
Mineral Oil Likely Accounts for Some - But Not All - of Vascepa's ASCVD Benefit
-
MIT Technology Review
Can you spot the fake receptor? The coronavirus can't either.
-
BioSpace
Startup Runs with Old Novartis Muscle Loss Drug to Fight Obesity
Previous
